Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3428]

Asciminib found to be safe and effective for heavily pretreated patients with...

Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA

Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase ( Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA )

Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first...

Prof Andrew Wei - Monash University, Melbourne, Australia

Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first remission after intensive chemo ( Prof Andrew Wei - Monash University, Melbourne, Australia )

Real world data supports ciltacabtagene autoleucel as effective option for...

Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca...

Real world data supports ciltacabtagene autoleucel as effective option for triple-class exposed r/r MM ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared...

Dr Martin Kaiser - The Institute of Cancer Research, London UK

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM ( Dr Martin Kaiser - The Institute of Cancer Research, London UK )

Latest in combination therapy for NDMM patients

Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA

Latest in combination therapy for NDMM patients ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )

Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail...

Dr Guido Gini - Università Politecnica delle Marche, Ancona, Italy

Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail patients with diffuse large B-cell lymphoma. ( Dr Guido Gini - Università Politecnica delle Marche, Ancona, Italy )

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma

Prof Ryan Lynch - University of Washington School of Medicine, Seattle, USA

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma ( Prof Ryan Lynch - University of Washington School of Medicine, Seattle, USA )

ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high...

Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center...

ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL) ( Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston, USA )

Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL

Prof Brian Hill - Cleveland Clinic, Cleveland, USA

Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL ( Prof Brian Hill - Cleveland Clinic, Cleveland, USA )

Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma

Prof Elizabeth Budde - City of Hope, Duarte, USA

Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma ( Prof Elizabeth Budde - City of Hope, Duarte, USA )

ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R...

Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center...

ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iNHL ( Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston, USA )

Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L...

Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora...

Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LBCL ( Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora, USA )

More from ecancer